The purpose of the study is to assess the effects of selexipag on right ventricular (RV)
function in participants with Pulmonary arterial hypertension (PAH).
The purpose of this study is to assess the long-term safety of selexipag while providing
continued selexipag treatment for participants who were previously enrolled in an
Actelion-sponsored study with selexipag and who derived benefit from selexipag in indications
for which a positive benefit-risk has been established.
This is a Phase 2, double-blind, randomized, placebo-controlled study to evaluate the
efficacy and safety of sotatercept versus placebo in adults with Cpc-PH due to HFpEF.
The objective of this study is to evaluate the efficacy, safety and tolerability of
sotatercept versus placebo in adults with Cpc-PH due to HFpEF. Efficacy is measured by change
from baseline in pulmonary vascular resistance (PVR, primary endpoint) and 6-minute walk
distance (6MWD, key secondary endpoint).
The objective of this study is to evaluate the effects of sotatercept treatment (plus maximum
tolerated background PAH therapy) versus placebo (plus maximum tolerated background PAH
therapy) on time to first event of all cause death, lung transplantation, or PAH
worsening-related hospitalization of ≥ 24 hours, in participants with WHO FC III or FC IV PAH
at high risk of mortality.
This is a two-part (Phase 2/Phase 3) study of MK-5475, an inhaled soluble guanylate cyclase
stimulator, in participants with pulmonary arterial hypertension (PAH).
The first part (Phase 2) will assess three different doses of MK-5475 compared to placebo in
a base period of 12 weeks, followed by comparison of three different doses of MK-5475 during
an optional 24 month extension period. The treatment dose with the best efficacy and safety
profile in the phase 2 cohort base period will be selected for use in the second part (Phase
3) of the study. The primary hypothesis of Phase 2 is that at least one MK-5475 dose is
The main purpose of this study is to evaluate the safety and tolerability of single dose of
treprostinil palmitil inhalation powder (TPIP) in participants with pulmonary arterial
A randomized, double-blind, placebo-controlled dose escalation and verification study to
assess the safety and efficacy of pulsed inhaled nitric oxide (iNO) in subjects at risk for
pulmonary hypertension associated with pulmonary fibrosis on long term oxygen therapy (Part 1
and Part 2) - REBUILD
This is a prospective, multicenter, open-label, randomized, controlled, parallel Phase 3
study with an open-label single-arm extension period to evaluate pharmacokinetics (PK),
safety and efficacy of macitentan in children with pulmonary arterial hypertension (PAH).
The purpose of the study is to evaluate the effect of macitentan 75 mg versus placebo on
exercise capacity at Week 28 in participants with chronic thromboembolic pulmonary
The main objective of the study is to assess the effect of treprostinil palmitil inhalation
powder (TPIP) compared with placebo on pulmonary vascular resistance.